CA3250398A1 - SPHINGOSIN-1-PHOSPHATE (S1PR) RECEPTOR MODULATOR INTENDED FOR USE IN THE TREATMENT OF A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA - Google Patents

SPHINGOSIN-1-PHOSPHATE (S1PR) RECEPTOR MODULATOR INTENDED FOR USE IN THE TREATMENT OF A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA

Info

Publication number
CA3250398A1
CA3250398A1 CA3250398A CA3250398A CA3250398A1 CA 3250398 A1 CA3250398 A1 CA 3250398A1 CA 3250398 A CA3250398 A CA 3250398A CA 3250398 A CA3250398 A CA 3250398A CA 3250398 A1 CA3250398 A1 CA 3250398A1
Authority
CA
Canada
Prior art keywords
s1pr
modulator
dementia
alzheimer
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3250398A
Other languages
English (en)
French (fr)
Inventor
Volkmar Leßmann
Kurt Gottmann
Thomas Endres
Georgia-Ioanna Kartalou
Original Assignee
Otto Von Guericke Universitaet Magdeburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otto Von Guericke Universitaet Magdeburg filed Critical Otto Von Guericke Universitaet Magdeburg
Publication of CA3250398A1 publication Critical patent/CA3250398A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3250398A 2022-03-31 2023-03-30 SPHINGOSIN-1-PHOSPHATE (S1PR) RECEPTOR MODULATOR INTENDED FOR USE IN THE TREATMENT OF A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA Pending CA3250398A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166162.2A EP4252748A1 (en) 2022-03-31 2022-03-31 A sphingosine-1-phosphate receptor (s1pr) modulator for use in treating a patient suffering from alzheimer's dementia
EP22166162.2 2022-03-31
PCT/EP2023/058360 WO2023187091A1 (en) 2022-03-31 2023-03-30 A sphingosine-1-phosphate receptor (s1pr) modulator for use in treating a patient suffering from alzheimer's dementia

Publications (1)

Publication Number Publication Date
CA3250398A1 true CA3250398A1 (en) 2023-10-05

Family

ID=81325093

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3250398A Pending CA3250398A1 (en) 2022-03-31 2023-03-30 SPHINGOSIN-1-PHOSPHATE (S1PR) RECEPTOR MODULATOR INTENDED FOR USE IN THE TREATMENT OF A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA

Country Status (5)

Country Link
US (1) US20250325501A1 (enExample)
EP (2) EP4252748A1 (enExample)
JP (1) JP2025510556A (enExample)
CA (1) CA3250398A1 (enExample)
WO (1) WO2023187091A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010264A1 (en) * 2009-03-26 2012-01-12 Dainippon Sumitomo Pharma Co., Ltd. Novel medicament for treating cognitive impairment
DK3081568T3 (da) * 2011-05-09 2020-02-24 Eip Pharma Llc Sammensætninger og fremgangsmåder til behandling af alzheimers sygdom
EP3193870A4 (en) * 2014-09-16 2018-04-25 Teva Pharmaceutical Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
EP3621610A1 (en) * 2017-05-08 2020-03-18 Celgene International II Sàrl Sphingosine 1 phosphate receptor agonists for neuroprotection
WO2019243453A1 (en) * 2018-06-19 2019-12-26 Universidad Pablo De Olavide Compositions for treating and/or preventing protein-aggregation diseases

Also Published As

Publication number Publication date
EP4252748A1 (en) 2023-10-04
US20250325501A1 (en) 2025-10-23
JP2025510556A (ja) 2025-04-15
EP4499056A1 (en) 2025-02-05
WO2023187091A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
JP5289765B2 (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
JP7368859B2 (ja) Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせを用いた神経系障害の治療
JP2025013604A (ja) 胆汁うっ滞を治療する方法
EP3560496A1 (en) Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
JP2002511409A (ja) 神経精神疾患の治療法
US11083700B2 (en) Butyrate salts for use in inflammatory diseases
JP2005527599A (ja) 肥満および摂食障害におけるゾニサミドの使用
HUE024558T2 (hu) Biotin alkalmazása szklerózis multiplex kezelésére
EP1313483A2 (en) Methods for inducing apolipoprotein e secretion
US20250188158A1 (en) Treatment of Parkinson's Disease
US20240277732A1 (en) Compositions and methods for treating brain-gut disorders
CN105517546A (zh) 治疗脆性x综合征及相关疾病的方法
JP2022514510A (ja) うつ病の治療方法
JP2018039817A (ja) 多発性硬化症を治療するためのＰＰＡＲγアゴニスト
US20230078820A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
CA2336151A1 (en) Pharmaceutical composition for the therapy of voiding dysfunction
WO2020165802A1 (en) Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
US20250325501A1 (en) A sphingosine-1-phosphate receptor (s1pr) modulator for use in treating a patient suffering from alzheimer's dementia
US20210315907A1 (en) Compositions and methods for treating brain-gut disorders
JP2005501108A (ja) 神経変性治療におけるネフィラセタムの使用
JP2002069003A (ja) ビタミンｄ誘導体を含有する骨吸収抑制剤
JP2003523385A (ja) 神経変性疾患の治療法
US20230372364A1 (en) Method of treating gaba mediated disorders
WO2005055997A1 (ja) 炎症性疾患の治療及び予防用医薬組成物
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240918

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250110

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250110

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250110

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: SMALL ENTITY DECLARATION DETERMINED COMPLIANT

Effective date: 20250110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250915

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251014

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251014

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251020

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251020

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251223

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260102

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260108